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Fragile X is the most common monogenic disorder associated with intellectual disability
(ID) and autism spectrum disorders (ASD). Additionally, many patients are afflicted with
executive dysfunction, ADHD, seizure disorder and sleep disturbances. Fragile X is
caused by loss of FMRP expression, which is encoded by the FMR1 gene. Both the fly
and mouse models of fragile X are also based on having no functional protein expression
of their respective FMR1 homologs. The fly model displays well defined cognitive
impairments and structural brain defects and the mouse model, although having subtle
behavioral defects, has robust electrophysiological phenotypes and provides a tool to
do extensive biochemical analysis of select brain regions. Decreased cAMP signaling
has been observed in samples from the fly and mouse models of fragile X as well as
in samples derived from human patients. Indeed, we have previously demonstrated
that strategies that increase cAMP signaling can rescue short term memory in the fly
model and restore DHPG induced mGluR mediated long term depression (LTD) in the
hippocampus to proper levels in the mouse model (McBride et al., 2005; Choi et al.,
2011, 2015). Here, we demonstrate that the same three strategies used previously with
the potential to be used clinically, lithium treatment, PDE-4 inhibitor treatment or mGluR
antagonist treatment can rescue long term memory in the fly model and alter the cAMP
signaling pathway in the hippocampus of the mouse model.
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INTRODUCTION
Fragile X syndrome is the most common monogenic cause
of both intellectual disability and autism spectrum disorders
(Turner et al., 1996; Crawford et al., 2002; Hagerman, 2008).
Fragile X is caused by the loss of FMR1 gene function, which is
caused by transcriptional silencing due to CGG repeat-expansion
induced hypermethylation in the promoter region, resulting in
loss of the gene product, FMRP. The incidence of Fragile X is
roughly 1 in 2500 to 1 in 4000 births (Pesso et al., 2000; Crawford
et al., 2001, 2002; Toledano-Alhadef et al., 2001; Hagerman,
2008). Symptoms associated with Fragile X almost always include
mild to severe developmental intellectual disability and can
include attention deficit hyperactivity disorder, seizures, sleep
disorders, anxiety and autism. FMRP is known to be enriched
both presynaptically and postsynaptically in neurons, and is
associated with and regulates a number of mRNAs in response
to synaptic activity (Jacquemont et al., 2007; Christie et al., 2009;
Darnell et al., 2011).
A Drosophila model for Fragile X syndrome, based on
the loss of dfmr1 expression, recapitulates several phenotypes
observed in Fragile X including impairments in social interaction
and several phases of memory including immediate recall
memory, short term memory and long term memory (Zhang
et al., 2001; Dockendorff et al., 2002; Morales et al., 2002;
McBride et al., 2005; Bolduc et al., 2008, 2010). Previous
studies in Drosophila have demonstrated that treatment with
lithium, metabotropic glutamate receptor (mGluR) antagonists
or phosphodiesterase type 4 (PDE-4) inhibitors can rescue
several phenotypes displayed by these flies including courtship
(social interaction), cognitive defects and a midline crossing
defect of the mushroom bodies in the brain (Dockendorff
et al., 2002; McBride et al., 2005; Bolduc et al., 2008; Choi
et al., 2010, 2015). However, a critical question when thinking
about attempting to move these compounds forward clinically
is which of these potential treatments have efficacy in rescuing
the long-term memory (LTM) impairments. In Drosophila
and in mammals, there are distinct phases of learning and
memory which have been distinguished through genetic and
pharmacologic dissection which often involve overlapping but
distinct signaling cascades and circuitry (Tully et al., 1994;
Yin et al., 1994; Greenspan, 1995; Yin and Tully, 1996; Kane
et al., 1997; Joiner and Griffith, 1999; McBride et al., 1999; Zars
et al., 2000; Kandel, 2001; Pascual and Preat, 2001; Kelleher
et al., 2004; Yu et al., 2004; Margulies et al., 2005; Guven-
Ozkan and Davis, 2014). Therefore treatments that rescue
learning/immediate recall memory (0–2 min memory) or short
term memory (60 min memory) may not rescue long term
memory.
We chose to examine three treatment strategies to examine
the efficacy on LTM in the fly model, all of which modulate
cAMP signaling in the fly. This is because cAMP signaling has
a central role in LTM formation and appears to be suppressed in
the fragile X fly and mouse models. Lithium, mGluR antagonists
and PDE-4 inhibitors have a common action of up-regulating
cAMP signaling. For lithium, the upregulation of cAMP signaling
is through the inhibition of glycogen synthase kinase-3beta
(GSK-3β) which is a known negative regulator of protein
kinase A (PKA; Fang et al., 2000; Li et al., 2000; Tanji et al.,
2002; McBride et al., 2005; Walsh et al., 2008; Min et al.,
2009a; See Figure 1A). The mGluR antagonists and PDE-4
inhibitors act more directly on the regulation of cAMP levels
(See Figure 1A). Adenylate cyclase synthesizes cAMP, which is in
turn degraded by phosphodiesterase (PDE) activity, with PDE-
4 being the most abundant cAMP specific PDE in the brain
of flies and mammals (Davis et al., 1989). PDE-4 inhibitors
directly increase cAMP levels after synaptic stimulation, by
inhibiting PDE-4 from degrading cAMP. In mammals, Group
II mGluRs predominantly couple to Gi signaling and suppress
adenylate cyclase activity upon stimulation, therefore antagonists
directly prevent the inhibitory actions of Gi signaling on cAMP
production and signaling (Sato et al., 2004). Recent studies
have also shown that Group I mGluRs can couple to Gi
(Kreibich et al., 2004), thus inhibition of both might raise
cAMP levels. In Drosophila, LY341495 and MPEP both bind
DmGluRA, the Drosophila mGluR that is coupled to both
Gi and Gq signaling. In mammals LY341495 is a Group II
mGluR antagonist and MPEP is a Group I mGluR antagonist
with the Group I mGluRs being predominantly coupled to Gq
signaling.
The most robust endophenotype to date in the Fragile X
mouse model is exaggerated metabotropic glutamate receptor
(mGluR)-dependent long-term depression (LTD) in the CA1
region of the hippocampus at 6–8 weeks of age to 11 months
of age (Huber et al., 2002; Hou et al., 2006; Nosyreva and
Huber, 2006; Choi et al., 2011, 2015). It is widely postulated that
long-term depression (LTD) as well as long-term potentiation
(LTP) may be cellular models of learning and memory. Chronic
treatments of fragile X mice with lithium, group I mGluR
antagonists, group II mGluR antagonists and PDE-4 inhibitors
have been demonstrated to abrogate the enhanced mGluR-LTD
phenotype (Choi et al., 2011, 2015; Michalon et al., 2012). In
contrast to the Drosophila Fragile X model, Fmr1 KO mice
display, at best, subtle behavioral and cognitive deficits that
can to be difficult to replicate (Bakker and Oostra, 2003;
Spencer et al., 2006). However, several groups have found that
audiogenic seizures, open field testing and cerebral protein
synthesis phenotypes can be reliably obtained and rescued
by lithium or GSK3B inhibition (Min et al., 2009a; Yuskaitis
and Jope, 2009; Mines et al., 2010; Yuskaitis et al., 2010;
Liu et al., 2011, 2012; Mines and Jope, 2011). More recently,
genetic reduction, short-term or long term pharmacologic
antagonization of group I mGluRs has successfully rescued some
phenotypes associated with the Fragile X mouse (Yan et al.,
2005; Hou et al., 2006; Dolen et al., 2007; De Vrij et al., 2008;
Michalon et al., 2012). Therefore, herein we complement the
fly studies on LTM by also examining the effect of chronic
treatments with lithium, group II mGluR antagonists and PDE-
4 inhibitors on brain and lymphocyte biochemistry in the
Fragile X mouse model in order to get a better understanding
of how these findings may translate into clinically beneficial
treatments. These treatments are similar to those used in the
fly (chronic treatment) and the treatment conditions used
are the same as those previously demonstrated to rescue the
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FIGURE 1 | Targeting the cAMP signaling cascade increases social interaction. (A) The cAMP signaling cascade. The three treatments used in this study
increase cAMP signaling in the fly and mouse. It has been demonstrated that antagonizing or dampening the signaling of either of the mGluR pathways can rescue
multiple phenotypes in the fly and mouse models of Fragile X including memory, audiogenic seizure and enhanced mGluR-LTD (McBride et al., 2005; Yan et al., 2005;
Dolen et al., 2007; Choi et al., 2010, 2011). Additionally, lithium has demonstrated efficacy in rescuing cognitive abilities, audiogenic seizure and enhanced mGluR-LTD
in fly and mouse models as well as in human patients (McBride et al., 2005; Berry-Kravis et al., 2008; Min et al., 2009b; Choi et al., 2010, 2011; Yuskaitis et al., 2010;
Liu et al., 2011). As is displayed in the figure, PDE-4 also intersects in this signaling cascade. The common aspect is that lithium, mGluR antagonists and PDE-4
inhibitors should all result in increasing cAMP signaling and increased PKA activity. Each should inhibit GSK-3B activity, which may be read out as phosphorylation of
tau. Tau phosphorylation has been demonstrated to phosphorylate and activate mTOR, although many pathways feed into mTOR signaling. (B–D) Social interaction
(Naive courtship of sham trained males) was examined after drug or vehicle treatment. (B–D) Naive courtship of WT and FS flies exposed to drug or drug vehicle
control containing food. Mean CIs (±SEM) are plotted; Ns are indicated above each bar for all groups. The comparisons shown on the graphs are between vehicle
and drug treatment with the same genotype and between WT and FS treatment for the vehicle treatment. For levels of significance, **p < 0.01; ***p < 0.001. Filled
bars indicate WT males; open bars indicate FS males. (B) Flies were raised on regular food and starting on the 1st day of adulthood placed on either vehicle control
food containing 5mM NaCl vehicle or food supplemented with 5 mM lithium. With vehicle treatment, FS males court virgin females less vigorously than do WT flies (p
< 0.001) represented by asterisks over the FS vehicle bar. FS flies treated with lithium spend a higher percentage of time engaged in courtship compared to vehicle
treated FS flies, asterisks above the FS lithium bar. WT flies treated with lithium demonstrated decreased courtship compared to vehicle treated WT flies, asterisks
over the WT lithium bar. (C) Flies were raised on regular food and starting on the 1st day of adulthood placed on either vehicle control food
(Continued)
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FIGURE 1 | Continued
containing DMSO vehicle or food supplemented with either 400 nM LY341495 or 8.6 µM MPEP. With vehicle treatment, FS males court virgin females less vigorously
than do WT flies, asterisks over the FS vehicle bar. FS flies treated with either MPEP or LY341495 spent a higher percentage of time engaged in courtship compared
to vehicle treated FS flies, asterisks over the FS LY341495 and FS MPEP bars. WT flies treated with either MPEP or LY341495 demonstrated decreased courtship
compared to vehicle treated flies, asterisks over the WT MPEP and WT LY341495 bars. (D) Flies were raised on regular food and starting on the 1st day of adulthood
placed on either vehicle control food containing DMSO vehicle or food supplemented with either 50 µM Rolipram (Roli) or 20 µM Ro-20-1724 (Ro-20). With vehicle
treatment, FS males court virgin females less vigorously than do WT flies, asterisks over the FS vehicle bar. FS flies treated with either rolipram or Ro-20-1724 spent a
higher percentage of time engaged in courtship compared to vehicle treated FS flies, asterisks above the FS rolipram and FS Ro-20-1724 bars. WT flies treated with
either rolipram or Ro-20-1724 demonstrated no change in the time spent engaged in courtship compared to vehicle treated flies.
aberrant mGluR LTD phenotype in the mouse (Choi et al., 2011,
2015).
RESULTS
Targeting the cAMP Signaling Cascade
with Three Distinct Pharmacological
Treatments
Wewill first describe the treatment paradigms used in our studies
then we will describe the results of these studies in the subsequent
sections.
Using Group II mGluR Antagonists to Up-Regulate
the cAMP Signaling Cascade
The mGluRs are G-protein coupled receptors. The Drosophila
genome contains a single metabotropic receptor (mGluR,
DmGluRA), and its characterization indicates it activates
signaling pathways downstream of both Gi and Gq (Parmentier
et al., 1996; McBride et al., 2005; Pan and Broadie, 2007; Pan
et al., 2008; Choi et al., 2010; Kanellopoulos et al., 2012). Gi alpha
activation inhibits adenylate cyclase (AC), thereby preventing an
increase in cAMP, which prevents PKA (protein kinase A) from
phosphorylating the activation site of CREB at serine 133, and
thereby reduces CREB-mediated gene transcription, a readout of
cAMP mediated signaling relevant to memory. In fact, altering
the activity of CREB can enhance memory in Drosophila and
additionally enhance long-term facilitation in Aplysia and LTP
in mice (Yin et al., 1994, 1995; Roman and Davis, 2001; Vitolo
et al., 2002; Bozon et al., 2003; Chen et al., 2003; Tully et al., 2003;
Kanellopoulos et al., 2012). LY341495 is a competitive antagonist
of the mammalian group II mGluRs, but has been shown to
inhibit theDrosophilamGluR, DmGluRA (Bogdanik et al., 2004).
MPEP is a selective group I mGluR5 non-competitive antagonist
in mammals, which also inhibits DmGluRA in Drosophila
through a conserved binding pocket for MPEP (McBride et al.,
2005). We used both MPEP and LY341495, to inhibit DmGluRA,
which in turn will prevent suppression of adenylate cyclase
activity maintaining or increasing cAMP signaling in the fly
(Kanellopoulos et al., 2012; Choi et al., 2015). DmGluRA is
coupled to both Gi and Gq signaling. We used LY341495 in
the mouse to antagonize Group II mGluRs again to maintain or
increase cAMP signaling in the mouse. We did not use MPEP for
mouse work in this study since the focus is on cAMP signaling
with regard to Fragile X models (Figure 1A) and in mammals at
low doses MPEP is selective for mGluR5 along with having a very
short half-life making chronic treatment difficult.
Using Lithium to Up-Regulate the cAMP Signaling
Cascade
At therapeutic doses lithium has been shown to inhibit
GSK-3β activity (Klein and Melton, 1996), and additionally
lithium treatment has been shown to facilitate CREB mediated
transcriptional activity (by inhibiting GSK-3B activity) in
cultured cells (Bullock and Habener, 1998; Grimes and Jope,
2001; Mai et al., 2002; Son et al., 2003). PKA inhibits GSK-3β
activity and GSK-3β has been shown to inhibit PKA activity,
therefore inhibiting GSK-3β relieves inhibition from PKA in the
cAMP signaling cascade providing the same effect that as a rise
in intracellular cAMP which promotes PKA activity (Fang et al.,
2000; Li et al., 2000; Tanji et al., 2002; Figure 1A).
Using PDE-4 Inhibitors to Up-Regulate the cAMP
Signaling Cascade
Previously studies of cAMP levels have determined that they are
low in the brains of both dfmr1 mutant flies and Fmr1 knockout
(KO) mice (Kelley et al., 2007; Choi et al., 2015) as well as in
flies that are heterozygous for a dfmr1 loss of function mutation
(Kanellopoulos et al., 2012). Decreased cAMP levels have also
been demonstrated in Fragile X patients (Berry-Kravis and
Huttenlocher, 1992; Berry-Kravis et al., 1995; Berry-Kravis and
Ciurlionis, 1998). Interestingly, FMR1 transcription is dependent
on CREB mediated transcription in flies and mammals, which
is activated by the cAMP pathway (Hwu et al., 1997; Cha-
Molstad et al., 2004; Kanellopoulos et al., 2012) and consistent
with these findings there is a positive correlation between FMRP
levels and cAMP levels in cell lines and platelets derived from
aﬄicted patients (Berry-Kravis and Huttenlocher, 1992; Berry-
Kravis et al., 1995; Berry-Kravis and Ciurlionis, 1998; Kelly et al.,
2007). This led to the hypothesis that one way to correct some
of the phenotypic cognitive deficits in Fragile X syndrome is
to increase cAMP to wild type physiologic levels. Although this
would not increase FMRP in patients (because it is silenced),
it would potentially increase levels of the other effectors in the
cAMP signaling cascade, which have been shown to play a role
in cognition (Impey et al., 2004). As shown in Figure 1A, PDE-
4 inhibition will prevent the breakdown of cAMP by PDE-4 and
thereby increase cAMP levels after synaptic stimulation thereby
increasing cAMP signaling cascade activity. This strategy has
previously been shown to be successful to rescue phenotypes in
the mouse and fly models of fragile X (Choi et al., 2015).
Indeed, it has previously been demonstrated that treatment
of the Fragile X fly model with lithium, mGluR antagonists
or PDE-4 inhibitors could rescue social interaction, immediate
Frontiers in Behavioral Neuroscience | www.frontiersin.org 4 June 2016 | Volume 10 | Article 136
Choi et al. Elevating cAMP Restores FXS LTM
recall memory and short term memory in the conditioned
courtship paradigm and odor shock paradigm in the fly model
(McBride et al., 2005; Bolduc et al., 2008; Choi et al., 2015) and
normalize DHPG induced mGluR mediated LTD in the mouse
model of fragile X when treatment is started in adulthood (Choi
et al., 2011, 2015; Michalon et al., 2012). The three strategies
should all increase cAMP signaling and lead to inhibited GSK-
3B activity. The decreased GSK-3β activity may be followed by
examining one of the well characterized substrates of GSK-3β
phosphorylation, which is the microtubule binding protein tau.
The Effects of Chronic Stimulation of cAMP
Signaling on Social Interaction in Fragile X
The Drosophila model of Fragile X is based on loss of function
of dfmr1, the Drosophila ortholog of FMR1. For our studies,
we use a dfmr1 deletion line carrying a genomic transgene
with a frame-shift mutation engineered in the dfmr1 coding
region that is driven by the endogenous promoter, referred to
as the FS line. The control line for these studies contains the
same deletion of the dfmr1gene, but also carries a wild type
transgene for dfmr1 that is driven by the endogenous promoter
and is referred to as the WT line (Dockendorff et al., 2002;
McBride et al., 2005; Banerjee et al., 2010). Both the FS and
WT lines are heterozygous for the transgenes and one copy of
the transgene provides approximately the same dfmr1 protein
levels as is seen in control lines. The baseline courtship values
in this manuscript are slightly higher than in our previous
papers (Dockendorff et al., 2002; McBride et al., 2005) due to a
different genetic background as in this paper we use the WT and
FS flies in an OreR background for the courtship experiments
(Banerjee et al., 2010). The fragile X model flies have previously
been shown to display social interaction deficits as assayed by
naïve (sham) courtship with virgin female targets (Dockendorff
et al., 2002; McBride et al., 2005; Banerjee et al., 2010; Choi
et al., 2010). Courtship activity has been studied for over a
century in the lab and is an indication of social interaction
in Drosophila (Sturtevant, 1915; Bastock, 1955, 1956; Spieth,
1974; Hall, 1994). Initially, this was heavily studied in with
examining courtship in pairs of males and females and later in
pairs of males and immature males. However, although a good
approximation of social interaction in reproductive situations,
social interaction can now also be studied in assays, which do
not intermingle reproductive drive as a variable. The assays
eliminating reproductive drive have now become valuable tools
in the field (Bolduc et al., 2010; Schneider et al., 2012; McNeil
et al., 2015).
Here again we found that although courtship is high enough to
expect memory formation after training, the fragile X flies display
naïve courtship that is significantly lower than WT (control) flies
for all three of the vehicle treatment groups (Figures 1B–D),
where the comparison is between the WT vehicle and FS vehicle
treatment flies for lithium (Figure 1B), mGluR antagonists
(Figure 1C) and PDE-4 inhibitors (Figure 1D). Fragile X flies
treated in adulthood with either lithium (Figure 1B), mGluR
antagonists (LY341495 orMPEP; Figure 1C) or PDE-4 inhibitors
(rolipram or Ro-20-1724; Figure 1D) displayed significantly
increased social interaction compared to each group of vehicle
treated Fragile X flies, which fits with the previous literature
(Figures 1B–D; McBride et al., 2005; Choi et al., 2010, 2015).
WT flies treated with either lithium or mGluR antagonists
(LY341495 or MPEP) displayed decreased social interaction
compared to vehicle treatment, which fits with the previous
literature (Figures 1B,C; McBride et al., 2005; Choi et al., 2010).
WT flies treated with PDE-4 inhibitors (rolipram or Ro-20-
1724) demonstrated a trend toward decreased social interaction,
but it did not reach significance (Figure 1D). In sum, these
data indicate that increasing cAMP levels in dfmr1 mutants can
rescue social interaction as measured in the courtship assay, but
additional increasing of signaling in this pathway is detrimental
to normal flies that presumably have optimized levels (see
Discussion).
The Effects of Chronic Stimulation of
cAMP Signaling on Long Term Memory in
Fragile X
Lithium Treatment in Adulthood Rescues LTM in
Fragile X Flies
Herein, we wanted to test if treatments begun in adulthood
could rescue LTM, as they have been demonstrated to rescue
social interaction and impairments in other phases of memory
in the fragile X model. In Drosophila, long-term memory can
be assessed in several ways and the two we utilize in this paper
are the conditioned courtship associative memory paradigm
and the olfactory conditioning associative memory paradigm.
In the series of experiments conducted during this study we
used the conditioned courtship paradigm extensively and we
confirmed those findings by doing a subset of key experiments in
the olfactory conditioning associative memory paradigm. Each
paradigm is able to stand alone as an assay of associative long
term memory, but in this case since work on the fragile X fly
model had previously been performed in both assays, we decided
that it would be helpful to use both assays but in the case of
the olfactory paradigm we only used one compound per class
of drugs to confirm the findings in the conditioned courtship
paradigm. Conditioned courtship and olfactory conditioning
(Pavlovian conditioning) have allowed for a genetic dissection
of each stage of memory formation from learning to long-
term memory in Drosophila (Quinn et al., 1974; Siegel and
Hall, 1979; Tully and Quinn, 1985; Tully et al., 1994; Yin
et al., 1994, 1995; McBride et al., 1999; Banerjee et al., 2010).
The conditioned courtship long-term memory paradigm takes
advantage of fly courtship behavior. If a male is paired with
a previously mated female over the course of 5–7 h (7 h in
this paper), his courtship will decrease during the training
period due to the female’s aversive cues and rejection of his
advances. When subsequently paired with a virgin female, 1–
9 days later (4 days later is used in this paper), a male will
continue to have suppressed courtship relative to a naive/sham
trained male that has not been exposed to a previously mated
female (McBride et al., 1999). This lower courtship activity is
indicative of a memory of the training. The courtship indices
(CIs), the percentage of time a male spends courting a female
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during a timed courtship interval, are used to calculate a memory
index (MI; Siegel and Hall, 1979; Keleman et al., 2007; see
methods). A larger MI value is indicative of memory and scores
closer to zero or negative values are indicative of no memory
of the training (Keleman et al., 2007). The fragile X flies have
already been shown to have impairments in long-term memory
in conditioned courtship (McBride et al., 1999; Banerjee et al.,
2010).
Previous studies have identified lithium as a potential
treatment for fragile X in fly and mouse models as well as in a
pilot trial in patients (McBride et al., 2005; Berry-Kravis et al.,
2008; Min et al., 2009a,b; Yuskaitis et al., 2010; Liu et al., 2011,
2012). In mouse studies this has been found, at least in part, to
be secondary to the effects of lithium inhibiting GSK-3β activity
(Klein and Melton, 1996; Mines et al., 2010, 2013; Yuskaitis et al.,
2010). Lithium can inhibit GSK-3β and thereby increase cAMP
signaling, whereas cAMP levels may be suppressed by the over-
active mGluR signaling in the fragile X fly model, mouse model
and cell lines derived from patients (Figure 1A; Berry-Kravis and
Huttenlocher, 1992; Berry-Kravis et al., 1995; Berry-Kravis and
Ciurlionis, 1998; McBride et al., 2005; Kelley et al., 2007; Choi
et al., 2015). Lithium is clinically FDA approved for the treatment
of Bipolar Disorder and is used off label for a number of other
psychiatric indications.
In order to test the hypothesis that lithium may rescue
cognitive impairments in Fragile X flies, FS and WT flies
were treated with lithium or the appropriate vehicle (the same
concentration of NaCl in the food) for 9 days starting on the
day of eclosion as an adult. Flies then underwent sham or LTM
training on day 10 and were subsequently placed back on lithium
or vehicle containing food for 3 days and tested for memory
of the training session on day 4 post training. The results are
graphed using a memory index and the results indicate whether
or not LTM is present in a particular paired comparison of sham
trained compared to LTM trained means. FS flies demonstrated
rescued LTM at 4 days post training after treatment with lithium
(Figure 2A), meaning there was a suppression of courtship in
the LTM trained group compared to the sham trained group
when the FS flies were treated with lithium as is graphically
shown by the higher memory index (Figure 2A). In contrast,
FS flies continued to have impaired LTM when treated with the
vehicle control, which fits with previously published literature
(Figure 2A). WT flies displayed intact LTM when treated with
lithium or vehicle (Figure 2A).
In order to determine if lithium treatment could rescue LTM
in the olfactory-based LTM memory paradigm, we examined
LTM in FS flies that were treated with lithium or vehicle. It
should be noted that in this paradigm the performance indices
are compared between different groups. The FS flies on vehicle
demonstrate worse LTM compared to the WT flies on vehicle
treatment (Figure 2B, p < 0.001). FS flies that were treated
with lithium displayed improved LTM compared to FS flies on
vehicle treatment (Figure 2B as indicated by the asterisks). This
represents a performance improvement in the FS flies, but not a
full phenotypic reversal. WT flies demonstrated similar LTM on
either lithium or vehicle treatment (Figure 2B).
FIGURE 2 | Long-term memory is rescued by lithium treatment in fragile X flies. (A) Long-term memory (4 days post training) was measured in WT and FS
flies that were administered vehicle control food or drug treatments contained in the food. Memory Index (±the error) was plotted; Ns are indicated above each bar for
all groups. The levels of significance are *p < 0.05; **p < 0.01; ***p < 0.001, and are generated from comparisons of same genotype, same treatment between LTM
trained and sham trained flies. Filled bars indicate WT males; open bars indicate FS males. Flies were raised on regular food and starting on the 1st day of adulthood
placed on either vehicle control food containing 5 mM NaCl vehicle or food supplemented with 5 mM lithium. With vehicle treatment, FS males did not display
long-term memory. FS flies treated with lithium did demonstrate long-term memory. WT flies treated with either vehicle or lithium demonstrated long-term memory. (B)
Lithium rescues the olfactory-based long-term memory defect observed in dfmr1 mutants. Flies were placed on LiCl or vehicle in food for 9 days prior to spaced
training. Long-term memory of olfactory conditioning after spaced training was significantly improved in FS mutants after being administered lithium. The levels of
significance are indicated as follows: ***p < 0.001. No effect of treatment was observed in WT controls.
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mGluR Antagonist Treatment in Adulthood
Rescues LTM in Fragile X Flies
Previous studies have identified a mGluR antagonist treatment as
a way to correct phenotypes for fragile X in the fly and mouse
models as well as to correct symptoms in an exploratory analysis
of 7 patients with full methylation of the promoter site in a
small trial in patients (McBride et al., 2005; Dolen et al., 2007;
Bolduc et al., 2008; Jacquemont et al., 2011; Michalon et al.,
2012). In order to test the hypothesis that mGluR antagonists
may rescue long-term memory in Fragile X flies, FS and WT flies
were treated with 2-methyl-6-(phenylethynyl) pyridine (MPEP),
LY341495 or the appropriate vehicle for 9 days starting on the
day of eclosion as an adult. Flies then underwent sham or LTM
training on day 10, and were subsequently placed back on MPEP,
LY341495 or vehicle containing food for 3 days and tested for
memory of training on day 4 post training. FS flies demonstrated
rescued LTM at 4 days post training after treatment with MPEP
or LY341495 (Figure 3A). In contrast, FS flies continued to have
impaired LTMwhen treated with the vehicle control (Figure 3A).
WT flies displayed intact LTM when treated with either of the
mGluR antagonists or vehicle (Figure 3A).
In order to determine if mGluR antagonist treatment
could rescue LTM in the olfactory-based LTM memory
paradigm, we examined LTM in FS flies that were treated
with LY341495 or vehicle. The FS flies on vehicle demonstrate
worse LTM compared to the WT flies on vehicle treatment
(Figure 3B, p < 0.001). FS flies that were treated with
LY341495 displayed improved LTM compared to FS flies
on vehicle treatment (Figure 3B as indicated by the asterisks).
This represents a performance improvement in the FS flies,
but not a full phenotypic reversal. WT flies demonstrated
similar LTM on either LY341495 or vehicle treatment
(Figure 3B).
PDE-4 Inhibitor Treatment in Adulthood
Rescues LTM in Fragile X Flies
Previous studies have demonstrated efficacy of PDE-4 inhibition
in rescuing phenotypes in the fly model and mouse model of
fragile X (Choi et al., 2015). In order to test the hypothesis that
PDE-4 inhibition may rescue LTM in Fragile X flies, FS and WT
flies were treated with rolipram, Ro-20-1724 or the appropriate
vehicle for 9 days starting on the day of eclosion as an adult.
Flies then underwent sham or LTM training on day 10, and were
subsequently placed back on rolipram, Ro-20-1724 or vehicle
containing food for 3 days and tested for memory of training
on day 4 post training. In mammals, both rolipram and Ro-
20-1724 are widely used as PDE-4 inhibitors and both have
been used in flies to inhibit PDE-4 at the concentrations used
herein (Kanellopoulos et al., 2012; Choi et al., 2015). Additionally,
the treatments have been shown to increase cAMP levels in
flies (Kanellopoulos et al., 2012; Choi et al., 2015). FS flies
demonstrated rescued LTMat 4 days post training after treatment
with rolipram or Ro-20-1724 (Figure 4A). In contrast, FS flies
continued to have impaired LTM when treated with the vehicle
FIGURE 3 | Long-term memory is rescued by mGluR antagonist treatment in fragile X flies. (A) Long-term memory (4 days post training) was measured in
WT and FS flies that were administered vehicle control food or drug treatments contained in the food. Memory Index (±the error) was plotted; Ns are indicated above
each bar for all groups. The levels of significance are *p < 0.05; **p < 0.01; ***p < 0.001, and are generated from comparisons of same genotype, same treatment
between LTM trained and sham trained flies. Filled bars indicate WT males; open bars indicate FS males. Flies were raised on regular food and starting on the 1st day
of adulthood placed on either vehicle control food containing DMSO vehicle or food supplemented with either 400 nM LY341495 or 8.6 µM MPEP. With vehicle
treatment, FS males did not display long term memory. FS flies treated with LY341495 or MPEP did demonstrate long term memory. WT flies treated with either
vehicle, MPEP or LY341495 demonstrated long term memory. (B) LY341495 rescues the olfactory-based long-term memory defect observed in dfmr1 mutants. Flies
were fed LY341495 or vehicle in the food for 9 days prior to spaced training. Long-term memory of olfactory conditioning after spaced training was significantly
improved in FS mutants after being administered LY341495. The levels of significance are indicated as follows: **p < 0.01; ***p < 0.001. No effect of treatment was
observed in WT controls.
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control (Figure 4A). WT flies displayed intact LTM when treated
with either of the PDE-4 inhibitors or vehicle (Figure 4A).
In order to determine if PDE-4 inhibition could rescue LTM in
the olfactory-based LTM memory paradigm, we examined LTM
in FS flies that were treated with rolipram. We have previously
shown that rolipram rescued short-term memory and did not
affect olfaction or shock sensation (Choi et al., 2015). The FS
flies on vehicle demonstrate worse LTM compared to the WT
flies on vehicle treatment (Figure 4B, p < 0.0001). FS flies that
were treated with rolipram displayed improved LTM compared
to FS flies on vehicle treatment (Figure 4B as indicated by the
asterisks). This represents a performance improvement in the FS
flies, but not a full phenotypic reversal. WT flies demonstrated
similar LTM on either rolipram or vehicle treatment (Figure 4B).
The Effects of Chronic Drug Treatments
That Rescue mGluR-LTD on Brain
Biochemistry
Previously it has been demonstrated that each of the three
treatments used to rescue LTM in the fragile X fly model
can also be used to rescue the phenotype of enhanced DHPG
induced mGluR mediated LTD (long term depression) in the
CA1 in the fragile X mouse model. It has been demonstrated
that an 8 week treatment initiated in adulthood with either
lithium, group II mGluR antagonist or PDE-4 inhibitor can
normalize DHPG induced mGluR-LTD, but the effects of such
prolonged treatments with these drugs under the conditions
that demonstrated rescued DHPG induced mGluR-LTD has not
been examined regarding brain biochemistry or lymphocyte
biochemistry in fragile X mice (Choi et al., 2011, 2015). For
the treatments with lithium or control chow or drug vs. vehicle,
all mice were weighed 2–3 times weekly. For drug and vehicle
injections, the injections were performed daily for 8 weeks
starting at 8 weeks of age.
The Effect of Chronic Lithium Treatment on
GSK-3β Phosphorylation
Lithium treatment inhibits GSK-3β activity by increasing
phosphorylation at serine 9 on GSK-3β and competing with
magnesium for the magnesium-binding site that is critically
involved in GSK-3β activation (Klein and Melton, 1996;
Grimes and Jope, 2001; Gurvich and Klein, 2002; Gould
and Manji, 2005). Additionally, lithium inhibits Inositol-1-
monophosphatase (IMPase) and Inositol polyphosphate 1-
phosphatase (IPPase) activity, thereby reducing free InsP3 levels
and lowering InsP3R mediated calcium signaling, which is also
shown to be involved in LTD and more specifically mGluR-LTD
in the hippocampus (Hallcher and Sherman, 1980; Baraban et al.,
1989; Berridge et al., 1989; Worley et al., 1989; Berridge, 1993;
Acharya et al., 1997, 1998; Fujii et al., 2000; Taufiq et al., 2005; Jo
et al., 2008). GSK-3β is thought to be constitutively active unless
it is inhibited by phosphorylation at serine 9. We did not find
differences between WT control and Fmr1 KO mice regarding
alpha tubulin or beta actin levels, fitting with the previously
FIGURE 4 | Long-term memory is rescued by PDE-4 inhibitor treatment in fragile X flies. (A) Long-term memory (4 days post training) was measured in WT
and FS flies that were administered vehicle control food or drug treatments contained in the food. Memory Index (±the error) are plotted; Ns are indicated above each
bar for all groups. The levels of significance are *p < 0.05; **p < 0.01; ***p < 0.001, and are generated from comparisons of same genotype, same treatment between
LTM trained and sham trained flies. Filled bars indicate WT males; open bars indicate FS males. Flies were raised on regular food and starting on the 1st day of
adulthood placed on either vehicle control food containing DMSO vehicle or food supplemented with either 50 µM Rolipram (Roli) or 20 uM Ro-20-1724 (Ro-20). With
vehicle treatment, FS males did not display long-term memory. FS flies treated with rolipram or R0-20-1724 did demonstrate long-term memory. WT flies treated with
either vehicle, rolipram or Ro-20-1724 demonstrated long-term memory. (B) Rolipram rescues the olfactory-based long-term memory defect observed in dfmr1
mutants, but does not alter memory after massed training. Flies 1–3 days of age were fed Rolipram overnight before and after spaced training. Long-term memory of
olfactory conditioning after spaced training was significantly improved in FS mutants after being administered rolipram. The levels of significance are indicated as
follows: ***p < 0.001. No effect was observed in WT controls.
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published literature. It should be noted that in the representative
traces there will appear to be more or less tubulin as less protein
was added to some lanes to ensure that the proteins of interest
that were being stained remained in the linear range and did
represent an example of phosphorylated vs. total protein levels
as shown on the graphs. There were no differences between WT
and Fmr1 KO mice on either control vehicle or lithium chow
treatment in total GSK-3β protein levels (Figure 5A). There was
not a significantly higher ratio of phosphorylated GSK-3β to total
GSK-3β in WT mice compared to Fmr1 KO mice on control
FIGURE 5 | The effect of lithium treatment on the phosphorylated and total levels of GSK-3β, tau and mTOR. Eight week old Fmr1 KO mice and
age-matched WT mice were administered lithium-containing chow or control chow ad libitum until 5 months of age. All data in the top and middle panels are
normalized to vehicle-treated WT mice. (*p < 0.05; ** p < 0.01; *** p < 0.001; n over each bar refers to number of mice). (A) Top Panel: There were no differences in
the ratio of phosphorylated GSK-3β (Ser 9) to total GSK-3β in the hippocampus of Fmr1 KO mice and WT mice after chronic lithium or control chow treatment. Middle
Panel: There was no difference in the ratio of total GSK-3β to total α-tubulin. Bottom Panel: Representative bands of pS9 GSK-3β, total GSK-3β and α-tubulin. (B) Top
Panel: There was an increased ratio of phosphorylated to total tau at S202 in Fmr1 KO mice compared to WT mice on control chow. Lithium treatment reduced the
ratio of phosphorylated to total tau in Fmr1 KO mice compared to control treated Fmr1 KO mice. Middle Panel: There was an increase in total tau protein in Fmr1 KO
mice compared to WT mice on control treatment. Lithium treatment decreased the total tau protein in Fmr1 KO mice. Bottom Panel: Representative bands of pS202
tau, total tau and α-tubulin. (C) Top Panel: There was an increased ratio of phosphorylated to total mTOR at S2448 in Fmr1 KO mice compared to WT mice on control
chow. Lithium treatment reduced the ratio of phosphorylated to total mTOR in Fmr1 KO mice compared to control treated Fmr1 KO mice. Middle Panel: There was no
difference in total mTOR protein in Fmr1 KO mice compared to WT mice on control treatment. Lithium treatment decreased the total mTOR protein in WT mice.
Bottom Panel: Representative bands of pS2448 mTOR, total mTOR and α-tubulin.
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vehicle chow treatment or lithium chow treatment (Figure 5A).
However, there was a trend to lithium treatment increasing the
ratio of phosphorylated GSK-3β to total GSK-3β in Fmr1 KO,
which has been demonstrated in some previous studies (Min
et al., 2009b; Yuskaitis et al., 2010; Liu et al., 2011).
The Effect of Treatment on GSK-3β
Mediated Phosphorylation of Tau
One of the most well characterized substrates of GSK-3β-
mediated phosphorylation is the protein tau at serine 202, which
was examined in order to get a more sensitive indication of
GSK-3β activity (Dumont et al., 2011; Cavallini et al., 2013;
Petry et al., 2014). There was increased total tau normalized to
tubulin in Fmr1 KO mice compared to WT mice on chronic
control chow (Figure 5B). There was also an increased ratio of
phosphorylated tau to total tau in Fmr1 KOmice vs. WTmice on
control chow treatment (Figure 5B). Therefore, Fmr1 KO mice
that are merely treated with control chow have increased levels of
total tau and an increased percentage of tau phosphorylation at
serine 202 compared to WT mice, indicating increased GSK-3β
activity.
Lithium treatment lowered the amount of total tau in Fmr1
KO mice compared to control chow treatment, returning it to
near the level of WT mice on control chow. Lithium had no
effect on total tau levels in WT mice (Figure 5B). In Fmr1 KO
mice, chronic lithium treatment significantly lowered the ratio of
phosphorylated tau compared to control vehicle chow treatment
(Figure 5B). This demonstrates that chronic lithium treatment
reduces the activity of GSK-3β with regard to phosphorylation
of the tau protein in Fmr1 KO mice. Chronic lithium treatment
did not lower the percentage of tau phosphorylation in WT
mice. This result for WT mice does not fit all previous findings
which have seen mixed effects on WT mice regarding tau
phosphorylation after lithium treatment, in our study we have
used an extended length of the treatment period compared to
previous studies, thereby allowing a longer time for the WTmice
to restore homeostatic balance of signaling (Hong et al., 1997;
Noble et al., 2005; Engel et al., 2006).
Chronic lithium administration to FTDP-17 tau and GSK-
3β overexpressing mice prevents tau hyperphosphorylation and
neurofibrillary tangle formation, but pre-formed neurofibrillary
tangles do not revert.
The Effect of Lithium Treatment on mTOR
Phosphorylation
Lithium treatment lowered the ratio of phosphorylated tau to the
control chow treatment in Fmr1 KO mice. These results raise
the question of whether or not the increased phosphorylation of
tau may result in altering the activity of proteins downstream
of tau, which may be rescued by lithium treatment. It has
been previously demonstrated that tau hyperphosphorylation
can lead to increased mTOR activity in neurons (Khurana
et al., 2006). Additionally, another potential consequence of
upregulated mGluR signaling is upregulated mTOR activity
since it has been demonstrated that DHPG-induced mGluR
activation enhances mTOR activity, and that mTOR activity
plays a role in DHPG-induced LTD (Hou et al., 2004; Banko
et al., 2006; Figure 1A). Increased group I mGluR activity,
through an unknown mechanism, results in increased GSK-
3β activity in Fragile X mice (Min et al., 2009b). This could
be through the coupling of group I mGluRs to Gi signaling,
since even though they are predominantly coupled to Gq, they
can also couple to a lesser degree to Gi in neurons (Kreibich
et al., 2004). Group II mGluR activation should also increase
GSK-3β activity through the activation of Gi signaling, leading
to decreased cAMP signaling and decreased PKA activation,
thereby relieving inhibition on GSK-3β signaling (Figure 1A).
Since tau is hyperphosphorylated and it had been previously
demonstrated that mTOR activity may be increased under
certain conditions in Fmr1 KO mice (Sharma et al., 2010), the
phosphorylation status of mTOR at S2448, which stimulates
activation, was investigated.
There was no difference in total mTOR protein in Fmr1
KO mice compared to WT mice on chronic control vehicle
chow. However, in WT, but not Fmr1 KO mice, lithium
treatment lowered the amount of total mTOR compared to
control chow treatment, whereas no effect was observed in
Fmr1 KO mice (Figure 5C). There was an increased ratio of
phosphorylated mTOR (s2448) to total mTOR in Fmr1 KO mice
vs. WT mice on control chow treatment (Figure 5C), fitting
with some but not all of the previous literature (Osterweil
et al., 2010; Sharma et al., 2010). Chronic lithium treatment
did not lower the ratio of mTOR phosphorylation in WT
mice, which fits with the finding that tau phosphorylation was
not altered by lithium treatment in WT mice (Figure 5B).
In Fmr1 KO mice chronic lithium treatment significantly
lowered the ratio of phosphorylated mTOR compared to
control vehicle chow treatment (Figure 5C). This demonstrates
that chronic lithium treatment reduces the activity of mTOR
signaling in Fmr1 KO mice and is consistent with lithium
treatment lowering tau phosphorylation in Fmr1 KO mice
(Figure 5B).
The Effect of Group II mGluR Antagonist
Treatment on GSK-3β Phosphorylation
Antagonizing group II mGluRs is predicted to increase PKA
activity after synaptic stimulation and thereby decrease GSK-
3β activity (Fang et al., 2000; Li et al., 2000; Tanji et al.,
2002; McBride et al., 2005). To determine if this is the case
we examined the effect of LY341494 and vehicle treatment
on WT and Fmr1 KO mice. It should be kept in mind that
this treatment involved injecting vehicle every day for 8 weeks
which is very different than the lithium treatment and is
thus not comparable to control chow treated groups, which
were merely weighed several times weekly. In WT and Fmr1
KO mice treated with vehicle no differences between total
GSK-3β protein levels were observed, but LY341495 treatment
decreased total GSK-3β protein levels in both WT and Fmr1
KO mice compared to the levels of the vehicle treated mice
(Figure 6A). Also, there was a significantly greater ratio of
phosphorylated GSK-3β to total GSK-3β in the vehicle-treated
Fmr1KOmice compared to vehicle-treatedWTmice. Treatment
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with LY341495 had no effect on the GSK-3β ratio in either WT
or Fmr1 KO mice compared to vehicle treatment within the
genotypes (Figure 6A). However, since the majority of GSK-3β
is constitutively active looking at the phosphorylated ratio is
not as sensitive as looking at a substrate that undergoes GSK-
3β mediated phosphorylation, particularly in this case where
the total level of GSK-3β protein was decreased by LY341495
treatment.
FIGURE 6 | The effect of LY341495 treatment on the phosphorylated and total levels of GSK-3β, tau and mTOR. Eight week old Fmr1 KO mice and
age-matched WT mice were administered LY341495 or vehicle injections for 8 weeks. All data in the top and middle panels are normalized to vehicle-treated WT mice
(*p < 0.05; ** p < 0.01; *** p < 0.001; n over each bar refers to number of mice). (A) Top Panel: There was an increased ratio of phosphorylated GSK-3β (Ser 9) to total
GSK-3β in the hippocampus of Fmr1 KO mice compared to WT mice receiving vehicle injection. LY341495 treatment did not alter the phosphorylation in Fmr1 KO or
WT mice. Middle Panel: There was no difference between the ratio of total GSK-3β to total α-tubulin in vehicle treated Fmr1 KO and WT mice. LY341495 treatment
decreased the levels of total GSK-3β in both Fmr1 KO and WT compared to vehicle treated mice. Bottom Panel: Representative bands of pS9 GSK-3β, total GSK-3β
and α-tubulin. (B) Top Panel: There was no difference in the ratio of phosphorylated to total tau at S202 in Fmr1 KO mice compared to WT mice that were vehicle
treated. LY341494 treatment reduced the ratio of phosphorylated to total tau in Fmr1 KO and WT mice compared to vehicle treated mice. Middle Panel: There was no
difference in total tau protein in Fmr1 KO mice compared to WT mice on vehicle treatment. LY341495 treatment decreased the total tau protein WT mice. Bottom
Panel: Representative bands of pS202 tau, total tau and α-tubulin. (C) Top Panel: There was a decreased ratio of phosphorylated to total mTOR at S2448 in Fmr1 KO
mice compared to WT mice on vehicle treatment. LY341495 treatment did not change the ratio of phosphorylated to total mTOR in Fmr1 KO or WT mice compared to
vehicle treated mice. Middle Panel: There was no difference in total mTOR protein in Fmr1 KO mice compared to WT mice on vehicle treatment. LY341495 treatment
did not change the total mTOR protein in Fmr1 KO or WT mice. Bottom Panel: Representative bands of pS2448 mTOR, total mTOR and α-tubulin.
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The Effect of Group II mGluR Antagonist
Treatment on GSK-3β Mediated
Phosphorylation of Tau
There were no differences in total tau protein levels between
WT and Fmr1 KO mice on chronic vehicle treatment
(Figure 6B), indicating that daily handling for injection may
have normalized total tau levels which could be related to
findings showing effects on tau by different intensities of
environmental enrichment (Billings et al., 2007; Hu et al.,
2010, 2013). Chronic LY341495 treatment did reduce total tau
levels in WT mice, but not in Fmr1 KO mice. Furthermore,
there was no difference in the ratio of phosphorylated to
total tau between vehicle-treated WT mice and vehicle-treated
Fmr1 KO mice (Figure 6B). Chronic LY341495 treatment did
decrease the percentage of tau phosphorylation at Ser-202 in
both WT and Fmr1 KO mice compared to vehicle-treated mice
(Figure 6B). This suggests that chronic LY341495 treatment
decreased GSK-3β activity in the WT and Fmr1 KO mice as
measured by examining the ratio of phosphorylated to total
tau.
The Effect of Group II mGluR Antagonist
Treatment on mTOR Phosphorylation
We next examined the effect of group II mGluR antagonist
treatment on mTOR expression and activity levels. We did
not find a difference in total mTOR between WT and Fmr1
KO mice on chronic vehicle treatment or LY341495 treatment
(Figure 6C). However, there was a lower ratio of phosphorylated
to total mTOR between vehicle-treated Fmr1 KO mice and
vehicle-treated WT mice (Figure 6C). This result could indicate
that handling of mice may act as a limited type of environmental
enrichment, as was seen with tau phosphorylation. Chronic
LY341495 treatment had no effect on the ratio of phosphorylated
mTOR in the WT or Fmr1 KO mice compared to vehicle
treatment (Figure 6C).
The Effect of PDE4 Inhibition on GSK-3β,
Tau, and mTOR Phosphorylation Levels
We next examined the effect of rolipram treatment on Fmr1 KO
and WT mice. These sets of mice were also injected with drug
or vehicle every day for 8 weeks. Total GSK-3β protein levels
were higher in Fmr1 KO mice on vehicle treatment than in WT
mice. Additionally, in both Fmr1 KO and WT mice rolipram
increased total GSK-3Beta levels. There was a significantly
lower ratio of phosphorylated GSK-3β to total GSK-3β in the
vehicle-treated Fmr1 KO mice compared to DMSO vehicle-
treated WT mice. Treatment with rolipram had no effect on
the GSK-3β ratio in either WT or Fmr1 KO mice compared to
vehicle treatment within the genotypes, although there was a
trend toward increasing phosphorylation in the Fmr1 KO mice
(Figure 7A).
We next examined total and phosphorylated levels of tau
and found that there were no differences in total tau protein
levels between WT and Fmr1 KO mice on chronic DMSO
vehicle treatment (Figure 7B), however rolipram treatment
increased total tau in both WT and Fmr1 KO mice. There
was no difference in the ratio of phosphorylated to total
tau between vehicle-treated WT mice and Fmr1 KO mice
(Figure 7B). Chronic rolipram treatment did however decrease
tau phosphorylation levels in Fmr1 KO mice vs. vehicle treated
Fmr1 KO mice (Figure 7B). This suggests that chronic rolipram
treatment decreased GSK-3β activity in the Fmr1 KO mice
as measured by examining the ratio of phosphorylated tau to
total tau.
Finally, we examined total and phosphorylated levels of
mTOR. We did not detect a difference in total mTOR
between vehicle treated WT and Fmr1 KO mice but rolipram
treatment increased total mTOR levels in both WT and Fmr1
KO mice (Figure 7C). There was no difference in the ratio
of phosphorylated to total mTOR between vehicle-treated
Fmr1 KO and WT mice and, chronic rolipram treatment
had no effect on the ratio of phosphorylated mTOR in
the WT or Fmr1 KO mice compared to vehicle treatment
(Figure 7C).
The Effect of Modulating cAMP Signaling
in Bioassay of ERK Activation in
Lymphocytes
There is an interest in developing bioassays in the fragile X
field that could potentially be minimally invasive and used
in the clinic (Berry-Kravis et al., 2008; Weng et al., 2008;
Erickson et al., 2011b; Hoeffer et al., 2012). By collecting blood
samples and isolating lymphocytes, the time course of ERK
activation in lymphocytes can be measured after phorbol-12-
myristate-13-acetate (PMA) treatment (Chow et al., 2001; Tong
et al., 2006), which has been utilized as a bioassay in fragile
X mice and patients (Berry-Kravis et al., 2008; Weng et al.,
2008; Erickson et al., 2011b). A major question was whether
these three treatments, which all increase cAMP signaling and
decrease GSK-3β mediated tau phosphorylation, would have
measurable effects in the signaling measured in this bioassay.
It has previously been shown that p-ERK activation after PMA
stimulation is slower in fragile X mice and patients and that
this deficit can be corrected by lithium treatment (Berry-Kravis
et al., 2008). We found that at the time point of 2 min after
ERK activation by PMA there was a difference between control
and Fmr1 KO mice on control chow. In mice on control
chow, Fmr1 KO mice had decreased p-ERK compared to WT
mice, which is consistent with the previous literature (Berry-
Kravis et al., 2008; Weng et al., 2008). Fitting with the previous
literature, lithium treatment normalized p-ERK levels to WT
levels (Berry-Kravis et al., 2008; Weng et al., 2008; Figure 8).
Additionally, both LY341495 and rolipram treatment normalized
p-ERK levels at 2 min post PMA stimulation. In contrast, the
vehicle treatments for each had no measureable effect on ERK
activation (Figure 8).
DISCUSSION
Social Interaction
Treatment with lithium, mGluR antagonists and PDE-4
inhibitors given in adulthood was able to increase social
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FIGURE 7 | The effect of rolipram treatment on the phosphorylated and total levels of GSK-3β, tau and mTOR. Eight week old Fmr1 KO mice and
age-matched WT mice were administered rolipram or DMSO vehicle injections for 8 weeks. All data in the top and middle panels are normalized to vehicle-treated WT
mice (*p < 0.05; **p < 0.01; ***p < 0.001; n over each bar refers to number of mice). (A) Top Panel: There was an decreased ratio of phosphorylated GSK-3β (Ser 9)
to total GSK-3β in the hippocampus of Fmr1 KO mice compared to WT mice receiving vehicle injection. Rolipram treatment did not alter the phosphorylation in Fmr1
KO and lowered it in WT mice. Middle Panel: There was an increased ratio of total GSK-3β to total α-tubulin in vehicle treated Fmr1 KO compared to WT mice.
Rolipram treatment increased the levels of total GSK-3β in both Fmr1 KO and WT compared to vehicle treated mice. Bottom Panel: Representative bands of pS9
GSK-3β, total GSK-3β and α-tubulin. (B) Top Panel: There was no difference in the ratio of phosphorylated to total tau at S202 in Fmr1 KO mice compared to WT
mice that were vehicle treated. Rolipram treatment reduced the ratio of phosphorylated to total tau in Fmr1 KO, but not in WT mice compared to vehicle treated mice.
Middle Panel: There was no difference in total tau protein in Fmr1 KO mice compared to WT mice on vehicle treatment. Rolipram treatment increased the total tau
protein Fmr1 KO and WT mice. Bottom Panel: Representative bands of pS202 tau, total tau and α-tubulin. (C) Top Panel: There was no difference in the ratio of
phosphorylated to total mTOR at S2448 in Fmr1 KO mice compared to WT mice on vehicle treatment. Rolipram treatment did not change the ratio of phosphorylated
to total mTOR in Fmr1 KO or WT mice compared to vehicle treated mice. Middle Panel: There was no difference in total mTOR protein in Fmr1 KO mice compared to
WT mice on vehicle treatment. Rolipram treatment increased the total mTOR protein in Fmr1 KO and WT mice. Bottom Panel: Representative bands of pS2448
mTOR, total mTOR and α-tubulin.
interaction, which is normally suppressed in the fragile X
flies. However, treatment of the control flies with lithium and
mGluR antagonists decreased social interaction. This finding fits
with previous work demonstrating that a heterozygous loss of
function mutation in DmGluRA can suppress social interaction
in flies (Schoenfeld et al., 2013).
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FIGURE 8 | Bioassay. ERK activation by PMA stimulation is altered in
lymphocytes by lithium, LY341495 or rolipram treatment in Fmr1 KO mice. The
number of T lymphocytes per field was set to count the same number of cells
for each analyzed sample. At 2 min after stimulation there was more p-ERK
staining in WT mice compared to Fmr1 KO on control chow. The time point of
2 min post stimulation is graphed with the unstimulated value subtracted from
the stimulated sample. Fmr1 KO mice on lithium chow treatment had
increased p-ERK compared to Fmr1 KO mice placed on control chow. Fmr1
KO mice on LY341495 treatment had increased p-ERK compared to Fmr1 KO
mice on vehicle treatment. Fmr1 KO mice on rolipram treatment had increased
p-ERK compared to Fmr1 KO mice on DMSO vehicle treatment *p < 0.05 and
**p < 0.01.
The Effects of Modulating cAMP Signaling
on LTM in the dfmr1 Mutants
In our initial studies of the Fragile X fly model we found that
lithium treatment given in development or adulthood rescues
social interaction, immediate recall and short-term memory
(McBride et al., 2005). Herein we have extended these findings
to include LTM. We demonstrate that treatment started in
adulthood is able to rescue LTM in the fly model of fragile X.
Since our initial studies with the Drosophila model, it has now
been demonstrated that lithium treatment can rescue the several
phenotypes in Fmr1 KO mice (Min et al., 2009b; Mines et al.,
2010; Choi et al., 2011; Liu et al., 2011, 2012; Melancon et al.,
2012; Hashimoto et al., 2013). Moreover in a recent open label
trial it has been shown that lithium can positively affect some
behaviors in Fragile X patients (Berry-Kravis et al., 2008).
Herein we have also found that treatment with mGluR
antagonists in adulthood can rescue LTM in the fly model
of fragile X. Previously it has been demonstrated that
pharmacologic treatment with mGluR antagonists in adulthood
alone could rescue social interaction, immediate recall and
short-term in the fly model of Fragile X (McBride et al., 2005;
Bolduc et al., 2008; Choi et al., 2010). Additionally, treatment
for 8 weeks in adulthood was able to normalize the mGluR
dependent LTD phenotype in Fmr1 KOmice (Choi et al., 2011).
Previous research has also shown that pharmacologic
treatment with PDE-4 inhibitors beginning in adulthood could
rescue social interaction, immediate recall and short-term in the
fly model of Fragile X (Choi et al., 2015). Additionally, treatment
for 8 weeks in adulthood was able to normalize the mGluR
dependent LTD phenotype in Fmr1 KO mice (Choi et al., 2015).
Herein we demonstrate that treatment with PDE-4 inhibitors in
adulthood was able to rescue LTM in two paradigms for LTM in
the fly model of fragile X.
The Effects of Modulating cAMP Signaling
in the Fmr1 KO Mice
To determine the impact of modulating cAMP levels on signaling
deficits in the Fragile X models, we turned to the mouse model.
This is because of the ability to dissect more homogenous
brain tissue and the readily available and validated antibodies.
We examined hippocampal signaling via western blot of mice
chronically treated (for 8 weeks in adulthood) with three distinct
strategies that have been shown to rescue DHPG induced mGluR
dependent LTD, which are lithium, LY341495 and rolipram
(Choi et al., 2011, 2015). We chose to focus on 3 potentially
critical nodes of signaling, GSK-3β, tau, and mTOR. We did not
find consistent changes in the ratio of phosphorylated to total
GSK-3β across the drug treatments. However, we examined the
phosphorylation of tau by GSK-3β as a surrogate marker for
GSK-3β activity and found that all three treatments were able to
reduce the ratio of phosphorylated to total tau.
It is interesting to note that tau hyperphosphorylation is
thought to play a role in two common neurodegenerative
diseases, Alzheimer’s disease and frontotemporal dementia. This
is an interesting similarity as we have already found a strong
genetic interaction between Drosophila dfmr1 and presenilin
(psn) genes. Psn is the Drosophila homolog of the vertebrate
presenilin genes (PS1 and PS2). In humans, mutation of PS1
or PS2 leads to familial Alzheimer’s disease (Small and Gandy,
2006). We previously reported that the psn and dfmr1 genes
genetically interact in a transheterozygous context to severely
affect social interaction in the courtship assay (McBride et al.,
2010). In studies by others, the amyloid precursor protein (APP)
mRNA has been shown to bind FMRP (Darnell et al., 2001,
2011), APP protein has been demonstrated to be upregulated
in the fragile X mouse (D’agata et al., 2002) and differential
processing of the fragments of ABeta 1-40 and ABeta 1-42 have
been demonstrated to occur in a similar manner as those linked
to some other presenilin FADmutations (Westmark et al., 2011).
Hyperphosphorylation of tau is thought to be a critical event in
the progression of both Alzheimer’s disease and frontotemporal
dementia (Small and Gandy, 2006).
In our biochemical studies, we did not find a common
effect from our drug studies on the ratio of phosphorylated to
total mTOR. Lithium treatment given for 8 weeks in adulthood
was able to reduce mTOR phosphorylation, but treatment with
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LY341495 and rolipram did not reduce mTOR phosphorylation.
This leaves open the question of how critical mTOR activity is to
the rescue of phenotypes in the fragile X model for exploration in
future studies. Since cAMP increases could potentially mediate
mTOR inhibition through increasing the activity of LKB1 to
activate AMPK or through PKA without requiring AMPK
activity changes, which may not result in changes in mTOR
phosphorylation, this highlights the need to look at proteins
downstream of mTOR activity as a potentially more accurate
marker of mTOR activity (Xie et al., 2011; Laplante and Sabatini,
2012).
Clinical Prospects
The three strategies to increase cAMP signaling all normalize p-
ERK levels (as a marker of activation) after PMA stimulation
in lymphocytes in the Fmr1 KO mice. These findings add
to a growing body of evidence that using lymphocytes as
surrogate markers for a bioassay of fragile X may be useful
in clinical studies (Berry-Kravis et al., 2008; Weng et al.,
2008; Erickson et al., 2011a; Hoeffer et al., 2012). Lithium is
currently available for other indications clinically and indeed
a small trial already yielded some positive results in Fragile X
patients (Berry-Kravis et al., 2008). Two PDE-4 inhibitors are
currently available clinically, apremilast approved for psoriatic
arthritis and roflumilast approved for the treatment of chronic
obstructive pulmonary disease. Both have poor blood brain
barrier penetration (Kavanaugh et al., 2015;Martinez et al., 2015),
although roflumilast has been demonstrated to have enough
blood brain barrier penetration to alter neuronal signaling
(Jabaris et al., 2015). Furthermore, resveratrol is a natural
compound found in red wine that has been studied regarding
anti-aging properties and in the context of Alzheimer’s disease.
Resveratrol crosses the blood brain barrier and has been shown
to be able to inhibit PDE4 activity and increase AMPK activity
which is downstream of PKA (Chung, 2012; Park et al., 2012;
Bitterman and Chung, 2015; Pasinetti et al., 2015). Neither PDE-
4 inhibitors, nor resveratrol has been studied in a clinical trial
involving Fragile X patients.
Currently, the only group II mGluR antagonist in Phase 1
clinical trials is BCI-838, for which the majority of preclinical
research has had a focus on depression and Alzheimer’s disease
(Hashimoto et al., 2013; Kim et al., 2014). In the fly there is
just one functional mGluR receptor which signals through both
Gi and Gq (Bogdanik et al., 2004). mGluR antagonist treatment
inhibits the Gi coupled signaling increasing cAMP levels after
synaptic stimulation activating PKA which inhibits GSK-3β and
thereby increase cAMP signaling (Figure 1A; Bogdanik et al.,
2004; McBride et al., 2005; Kelley et al., 2007; Kanellopoulos et al.,
2012; Choi et al., 2015). This work adds to the current literature
in favor of clinical trials for each of these potential treatments in
fragile X.
MATERIALS AND METHODS
Drosophila Strains and Drug Testing
The Drosophila strains were cultured as in Dockendorff et al.
(2002), McBride et al. (2005), and Banerjee et al. (2010). For
flies tested in the courtship studies are from Banerjee et al.
(2010), so that the eye color is slightly more red to enhance
naive courtship equally in the FS and WT flies, these lines were
derived from the original FS and WT lines from Dockendorff
et al. (2002). Drugs were obtained from Tocris-Cookson (UK),
solubilized according to manufacturer’s instructions and mixed
into solid fly food at the appropriate concentration. Vehicle for
each drug was added to the appropriate control food for each
experiment. For the lithium treatment courtship experiments we
used 5 mM LiCl or a 5 mM NaCl vehicle treatment. For the
mGluR antagonist courtship experiments we used 8.6 µMMPEP
or 400 nM LY341495 or a DMSO vehicle treatment. For the
PDE-4 inhibitor courtship experiments we used 50µM rolipram,
and 20 µM Ro-20-1724 in the experiments presented with a
DMSO vehicle. For the courtship studies flies were placed on the
food on the day of eclosion until the night before the training
session and then placed back on drug containing food until the
night before testing. For olfactory classical conditioning, we used
50 µM rolipram with 5% sucrose and 5% DMSO on a filter
paper. Flies were fed overnight after having been starved for
3 h. The flies were trained and tested the next morning. The
control consisted of 5% sucrose and 5% DMSO. For lithium
(5mM) and LY341495 (600 nM), 1–3 days old flies were placed
on drug/vehicle containing food for 9 days prior to space training.
Behavioral Training and Testing in the
Conditioned Courtship Paradigm
Virgin male flies were collected under anesthesia and all testing
was performed as previously described (McBride et al., 1999,
2005; Choi et al., 2010). Male flies were collected and placed
on either vehicle or drug treatment for 10 days after eclosion.
Virgin XX, yf females were collected on the day of eclosion
and kept in food vials. Flies were aged in a 12:12 LD before
behavioral training and testing was performed during the relative
light phase. All male subjects were transferred to fresh control
food the day before testing and assigned to random groups for
blinded behavioral training and testing. All training and testing
was performed blind to genotype and treatment. A courtship
(CI) was calculated following testing as the percentage of total
observation time spent courting (Siegel and Hall, 1979; McBride
et al., 2005). A memory index was calculated as CI naive-CI
trained/CI naive × 100, the error calculated for the memory
index was the average of the standard errors of the naive and
trained groups scaled to the calculated memory index, keeping
the percentage of error the same (Keleman et al., 2007). Sensory
and motor testing for these treatments has been published on
previously for these flies (McBride et al., 2005; Choi et al., 2010,
2015).
Courtship-Based Long-Term Memory
Long-term memory training was performed in flies that were
10 days post eclosion and then testing was performed on the
fourth day post training as described previously (McBride et al.,
1999; Banerjee et al., 2010). Statistical analyses was performed
as described previously with courtship indices (CIs) of tested
males were subjected to arcsin square root transformations to
approximate normal distributions (McBride et al., 1999, 2005).
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ANOVAs and unpaired student t-tests were performed on
planned comparisons of arcsin square root transformed data
with the post-hoc analysis used for the comparisons being
the Bonferroni analysis. Since some of the set of data could
not be proven to be normal we proceeded with performing
non parametric Mann–Whitney U test on all of the planned
comparisons (naive vs. trained) (Siegel, 1957; Keleman et al.,
2007) to generate the critical p-values that are shown in the
figures (McBride et al., 1999, 2005; Banerjee et al., 2010;
Schoenfeld et al., 2013). For all of the comparisons there
was agreement between the statistical tests either using the
ANOVAs with Bonferroni analysis or the Mann-Whitney U test
as to whether or not the comparison achieved significance. All
statistics were performed using Statview 3.0 and Prism 5.0.
Pavlovian Olfactory Learning and Memory
Drosophila were raised at 22◦C and placed at 25◦C overnight
prior to behavioral experiments. Adult Drosophila 3–5 days old
were trained and tested with the classical conditioning procedure
of Tully and Quinn (1985). Flies were treated with either drug
or vehicle contained in the food for 1 day prior to testing. About
100 flies were trapped inside a training chamber, covered with an
electrifiable copper grid. Flies were allowed 90 s to acclimate and
then were exposed sequentially to two odors, 3-octanol (OCT)
and 4-methylcyclohexanol (MCH), carried through the chamber
in a current of air (750 mL/min; relative concentrations of OCT
andMCHwere adjusted so that naive flies distributed themselves
50:50 in the T-maze). Flies first were exposed for 60 s to the
conditioned stimulus (CS+; either OCT or MCH), during which
time they received the unconditioned stimulus (US; twelve 1.25 s
pulses of 60V DC electric shock at 5 s interpulse intervals). After
the CS+ presentation, the chamber was flushed with fresh air for
45 s. Then flies were exposed for 60 s to a second, control stimulus
(CS-; either MCH or OCT depending on the odor the flies were
shocked to in the first step), which was not paired with electric
shock. After the CS-presentation, the chamber was again flushed
with fresh air for 45 s. The training was repeated for 10 times
with 15 min rest interval for memory after spaced training. For
training of massed training, 10 training sessions are provided but
without rest interval. At 1 day after training, flies are inserted in
the t-maze. To test for conditioned odor avoidance after classical
conditioning, flies were tapped gently from the training chamber
into an elevator-like compartment that transports them to the
choice point of the T-maze. Ninety seconds later, the flies were
exposed to two converging current of air one carrying OCT,
the other MCH, from opposite arms of the T-maze. Flies were
allowed to choose between the CS+ and CS− for 120 s, at which
time they were trapped inside their respective arms of the T-maze
(by sliding the elevator out of register), anesthetized and counted.
Two groups of flies were trained and tested in one complete
experiment. The CS+ was OCT and the CS− was MCH for one
group; the CS+ was MCH and the CS− was OCT for the second
group.
Drug Feeding
For acute feeding, flies were starved for 4 h and then place in a
vial containing a filter paper with 200 µL of solution. The vehicle
contained 5% sucrose with DMSO 5% for Rolipram. Flies were
exposed to 50 µM for the treatment.
Analysis of the Olfactory Memory Performance
The performance index (PI) was calculated as the average of the
fraction of the population avoiding the shock-associated odor
minus the fraction avoiding the control odor for each group of
flies trained in one experiment. In other words, the PI enumerates
the distribution of flies in the T-maze as a normalized “percent
correctly avoiding the shock-paired odor” and ranges from 0
for a 50:50 distribution to 100 for a 100:0 distribution. Data
from an experiment were subjected to a one-way ANOVA (JMP
from SAS, Inc.), followed by planned pairwise comparisons as
indicated in text and figure legend. An α = 0.05 was corrected
formultiple comparisons using Bonferroni. Post-test analysis was
performed with Tukey test. Comparisons with one, two, or three
asterisks indicate significances of P < 0.05, 0.001, and 0.0001,
respectively. All graphs depict mean± s.e.m.
Mouse Studies
All animal studies were conducted in accordance with protocols
approved by the Institutional Animal Care and Use Committee
at the Drexel University College of Medicine and Albert Einstein
College of Medicine. Mice that are homozygous (female) or
hemizygous (male) for a targeted mutation in the Fmr1 gene on
the X chromosome and backcrossed for 11 generations onto the
FVB background were purchased from the Jackson Laboratory
(Bar Harbor, ME) and bred in-house (Fmr1 KO mice, stock
number 004624; Bakker et al., 1994). Mice of the appropriate
control strain were also purchased from Jackson and bred in-
house (stock number 004828). To verify the genotype of the
animals, DNA was extracted from tail tissue and the following
primers were used for PCR analysis: mutant primers 5′-CCg gTT
CTT TTT gTC AAg ACC g-3′ and 5′-Cgg CAg gAg CAA ggT
gAg AT-3′; wild-type primers 5′-gTg gTT AgC TAA AgT gAg
gAT gAT-3′ and 5′-CAg gTT TgT Tgg gAT TAA CAg ATC-3′.
All mice were subjected to a 12 h:12 h light: dark cycle. Food and
water were provided ad libitum. Only male mice were used for
experimentation in this paper.
Drug Administration
Drug treatments were performed using the same treatment
protocols utilized in Choi et al. (2011) and Choi et al. (2015).
R, S-DHPG and LY341495 were purchased from Tocris (St.
Louis, MO). DHPG was solubilized as a 50 mM stock in water;
LY341495 was prepared as 100 mM stock in equimolar NaOH as
recommended by the company. Solubilized drugs were aliquoted
and frozen at −20◦C. Fresh stocks were prepared weekly for
DHPG, and biweekly for LY341495 and NaOH vehicle.
LY341495
Eight week old male Fmr1 KO mice and age-matched male
control mice were administered 0.9% saline containing 0.3 mg/kg
LY341495 or vehicle alone via subcutaneous injections once daily
for 8 weeks. This dose has previously been to shown to be the
lowest dose that reverses the in vivo effects of a group II mGluR
agonist (Ornstein et al., 1998). The mice were given at least a
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2-week drug and handling hiatus prior to testing. Mice were
weighed weekly to help monitor general well-being.
Lithium
Eight week old male Fmr1 KO mice and age-matched male WT
control mice were administered custom-made chow containing
2.4 g/kg lithium carbonate or vehicle (Bio-Serv, Frenchtown,
NJ) for 8 weeks. This dose and route of administration
have previously been shown to achieve clinically relevant
concentrations of serum lithium (0.6–1.2 mM) in mice (Son
et al., 2003; Su et al., 2004; Choi et al., 2011). Food and water
were provided ad-libitum. Serum lithium concentration was
determined by collecting trunk blood, isolating the serum by
centrifugation (11,000 rpm, 5 min) and then utilizing services
provided by the Hospital of the University of Pennsylvania.
The tested samples of trunk blood demonstrated that the serum
lithium concentration was in the clinically relevant range for all
treated mice and none of the control mice. Mice were weighed 2
to 3 times weekly to help monitor general well-being.
Western Blotting
Mice were deeply anesthetized using isoflurane and decapitated.
Hippocampi were immediately dissected on ice and placed in ice-
cold homogenization buffer (in mM: HEPES, 5; MgCl2, 1; EGTA,
2; sucrose, 0.32; protease and phosphatase inhibitors). The tissue
was homogenized in a 7mL glass homogenization tube using 25
strokes, transferred to new tubes and sonicated; the temperature
was maintained at 4◦C throughout all procedures. Protein assay
was performed on the samples before storing them at−80◦C.
For Western blotting, 30–60 µg of protein from the
hippocampal lysates were separated by SDS-PAGE and
transferred to nitrocellulose membranes, which were blocked
(5% milk in 1x TBS and 0.01% Tween-20) then probed with
primary followed by secondary antibodies. For sequential
blotting, the membranes were stripped (Restore Western Blot
Stripping Buffer, Pierce, IL), washed (1X TBS with 0.01% Tween-
20) then reprobed with primary and secondary antibodies. All
membranes were developed using enhanced chemiluminescent
detection (Amersham, NJ). Western blots were analyzed
using ImageJ software (NIH, MD) for densitometric
analysis and normalized to the quantity of α-tubulin and
β-actin.
Antibodies against GSK-3β (total and phospho Ser-9), mTOR
(total and phospho Ser-2448), β-actin and α-tubulin were
purchased from Cell Signaling (Danvers, MA). Antibodies
against tau (DP9 against total tau and CP13 against phospho Ser-
202) were generous gifts from Dr. Peter Davies (Albert Einstein
College of Medicine). Statistical analysis was performed as
described previously (Sharma et al., 2010) with arcsin square root
transformations to approximate normal distributions (McBride
et al., 1999, 2005) and one way ANOVAs were performed on
planned comparisons of arcsin square root transformed data
with the post-hoc analysis used for the comparisons being the
Bonferroni analysis.
ERK Activation Assay
ERK activation assay was performed as described in Weng
et al. (2008) and Berry-Kravis et al. (2008). AlexaFluor
647 was used for staining of p-ERK ½ (MAPK42/44)
(purchased from Cell Signaling). For these studies multiple
time points after PMA stimulation were measured by flow
cytometry, only the 2 min time point minus the 0 min
unstimulated time point are graphed. Statistical analysis
was performed by the Mann-Whitney test on preplanned
comparisons.
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